Theoretical stack · Cognition & Sleep

Semax + Selank

The Russian cognitive stack

Emerging

Theoretical educational discussion

This page summarizes a peptide combination as discussed in the research and user communities. It does not constitute medical advice, dosing recommendations, or instructions for personal use. Combination-specific human RCT evidence is generally absent for these stacks; per-compound evidence does not transfer additively to combinations.

Decisions about peptide therapy require an appropriately licensed clinician. We do not sell peptides.

At a glance

The most-discussed nootropic peptide combination. Semax provides the cognitive / focus arm (ACTH-fragment-derived); Selank provides the anxiolytic / calming arm (tuftsin-derived). Both originate from the same Russian neuropeptide research lineage.

Compounds in the stack

Each compound's role in the combination, with link to its full peptide page for the underlying research.

Semax
Russian synthetic heptapeptide derived from ACTH(4-10); claimed cognitive support, neuroprotection
Investigational outside Russia · Intranasal
Selank
Russian synthetic heptapeptide derived from tuftsin; claimed anxiolytic and immunomodulatory effects
Investigational outside Russia · Intranasal

Mechanistic rationale

The two-peptide framing splits the cognitive-and-mood landscape into a stimulating arm and a calming arm:

  • Semax is positioned as cognitive enhancement / focus / neuroprotection, with mechanistic claims around BDNF modulation and dopaminergic support.
  • Selank is positioned as anxiolytic without sedation, with claims around GABA and serotonergic modulation plus immunomodulatory effects.

The combination logic is straightforward — cognitive support without the anxiety / activation that pure stimulants would produce. The Russian research lineage that generated both compounds shares the same theoretical framework around "regulatory peptides."

Human and emerging evidence

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

Reported user experiences

Potential benefits and risks

Potential benefits

  • Mechanistically complementary (activation + calming)
  • Intranasal delivery is convenient and low-burden
  • Tolerability reports are generally favorable
  • Per-compound preclinical literature is substantial

Potential risks

  • Western-language RCT evidence is limited; positive evidence is concentrated in Russian-language journals
  • Claims about BDNF and neuroprotection mechanisms outpace controlled human data
  • Long-term safety in healthy adults is not characterized
  • Source quality varies in research-peptide markets
  • Not approved by FDA / EMA

Open questions

  • Are the Russian-research findings reproducible in independently-funded Western trials?
  • What is the long-term cognitive and safety profile in healthy adults?
  • Does the cognitive arm of the stack provide effects beyond placebo response in attention / focus tasks?

The takeaway

Semax + Selank is the canonical Russian-origin cognitive peptide stack. The pharmacology has a meaningful research lineage, the user-community reports are consistent enough to deserve attention, and the intranasal delivery format is practical. The honest gap is the Western-evidence framework — most positive RCT data is from a single research lineage and has not been independently replicated at scale outside Russia. For readers drawn to this combination, intellectual interest is fair; firm clinical conclusions are not yet supported.

References

  1. Eremin KO, et al. Semax: an analog of ACTH(4-10) — neuroprotective effects in cerebral ischemia. Bull Exp Biol Med. 2005;139(4):444-447. https://pubmed.ncbi.nlm.nih.gov/16027836/
  2. Kozlovskaya MM, et al. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(9):927-933. https://pubmed.ncbi.nlm.nih.gov/14969434/